Abstract
Background Many sub-Saharan Africa countries are scaling up differentiated service delivery (DSD) models for HIV treatment to increase access and remove barriers to care. We assessed factors associated with attrition after DSD model enrollment in Zambia, focusing on patient-level characteristics.
Methods We conducted a retrospective record review using electronic medical records (EMR) of adults (≥15 years) initiated on antiretroviral (ART) between 01 January 2018 and 30 November 2021. Attrition was defined as lost to follow-up (LTFU) or died by November 30, 2021. We categorized DSD models into eight groups: fast-track, adherence groups, community pick-up points, home ART delivery, extended facility hours, facility multi-month dispensing (MMD, 4–6-month ART dispensing), frequent refill care (facility 1-2 month dispensing), and conventional care (facility 3 month dispensing, reference group). We used Fine and Gray competing risk regression to assess patient-level factors associated with attrition, stratified by sex and rural/urban setting.
Results Of 547,281 eligible patients, 68% (n=372,409) enrolled in DSD models, most commonly facility MMD (n=306,430, 82%), frequent refill care (n=47,142, 13%), and fast track (n=14,433, 4%), with <2% enrolled in the other DSD groups. Retention was higher in nearly all DSD models for all dispensing intervals, compared to the reference group, except fast track for the ≤2 month dispensing group. Retention benefits were greatest for patients in the extended clinic hours group and least for fast track dispensing.
Conclusion Although retention in HIV treatment differed by DSD type, dispensing interval, and patient characteristics, nearly all DSD models out-performed conventional care. Understanding the factors that influence the retention of patients in DSD models could provide an important step towards improving DSD implementation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for the study was provided by the Bill & Melinda Gates Foundation through OPP1192640 to Boston University. YJ is supported by the Ruth L. Kirschstein National Research Service Award, National Institutes of Health F32 Individual Fellowship Grant (grant number: 1F32MH128120-01). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of: 1. the ERES Converge IRB (Zambia), 2. the Human Research Ethics Committee (Medical) of the University of Witwatersrand, and 3. the Boston University IRB gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
YJ: Youngji.Jo{at}bmc.org, LJ: ljamieson{at}heroza.org, BP: bphiri{at}clintonhealthaccess.org, AG: anna.grimsrud{at}iasociety.org, MM: muya.mwansa{at}gmail.com, HS: hshakwelele{at}clintonhealthaccess.org, PH: phaimbe{at}clintonhealthaccess.org, MMM: Mpande.Mwenechanya{at}cidrz.org, PLM: priscillalloyd2{at}icloud.com, BEN: brooken{at}bu.edu, SR: sbrosen{at}bu.edu
Analysis revised to include competing risks, accounting for transfers to other healthcare facilities.
Data Availability
Raw data were obtained from Zambia's national electronic medical record system. Derived data supporting the findings of this study are available from the corresponding author [SR] on request.